Skip to main
ERAS

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Erasca is poised for success with a focused RAS/MAPK pathway pipeline and promising clinical data for both ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. The potential for multi-blockbuster opportunities and strong management execution are expected to drive continued growth for the company. With a growing confidence in ERAS-0015's potential as a best-in-class pan-RAS therapy, a 25% probability of success, and an increase in our price target to $15, we maintain a Buy rating on Erasca.

Bears say

Erasca is currently focusing on developing therapies for RAS/MAPK pathway-driven cancers, but their potential advantage of ON/OFF RAS suppression through their molecular glue mechanism and high cyclophilin A binding affinity is still in question. The primary concerns for their clinical translation include establishing proof of concept for their deep pathway suppression and their potential to show responses in patients with varying KRAS alleles, while management's prioritization of indications for early monotherapy and comparison to mutant selective KRAS inhibitors remains important for future success.

Erasca Inc (ERAS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 9 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.